Most Popular
-
1
First-ever meeting of president, opposition chief set to finally happen
-
2
Blinken calls on China to press N. Korea to end its 'dangerous' behavior
-
3
Naver’s Line ownership in jeopardy as Japan ups pressure
-
4
South Korea to launch space security center under spy agency
-
5
Hybe refutes Ador CEO Min's denial of breach of trust
-
6
S. Korea, Japan could consider simplified entry agreement: Seoul official
-
7
New celebrity-endorsed therapy for face contouring requires only a pair of rubber bands
-
8
[Weekender] How DDP emerged as an icon of Seoul
![[Weekender] How DDP emerged as an icon of Seoul](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050915_0.jpg&u=)
-
9
Doctor group's incoming head renews call for govt. to scrap medical school quota hike for dialogue
-
10
[Herald Interview] Guggenheim Museum makes a push for technology-based art with LG
![[Herald Interview] Guggenheim Museum makes a push for technology-based art with LG](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/26/20240426050608_0.jpg&u=20240428114717)
![[Weekender] How DDP emerged as an icon of Seoul](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050915_0.jpg&u=)
![[Herald Interview] Guggenheim Museum makes a push for technology-based art with LG](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/26/20240426050608_0.jpg&u=20240428114717)
[THE INVESTOR] Samsung Bioepis announced on Sept. 12 that its biosimilar Brenzys has been granted approval for sale in Canada.
Its reference drug is Enbrel (etanercept), an autoimmune disease treatment developed by Amgen and sold by Pfizer that has raked in 10 trillion won (US$9.02 billion) worldwide.
The knockoff version has won approval from South Korean Ministry of Food and Drug Safety in September 2015; in Europe in January under trade name Benepali; and in Australia in July.
It will be sold by Merck Canada as a treatment for rheumatoid arthritis and ankylosing spondylitis, an arthritis that primarily affects the spine.
The biopharmaceutical unit of Samsung reported that Brenzys had similar efficacy and safety to the original medicine in a phase 3 clinical trial carried out in 10 countries with 596 patients with rheumatoid arthritis.
By Hwang You-mee (glamazon@heraldcorp.com)
Its reference drug is Enbrel (etanercept), an autoimmune disease treatment developed by Amgen and sold by Pfizer that has raked in 10 trillion won (US$9.02 billion) worldwide.
The knockoff version has won approval from South Korean Ministry of Food and Drug Safety in September 2015; in Europe in January under trade name Benepali; and in Australia in July.
It will be sold by Merck Canada as a treatment for rheumatoid arthritis and ankylosing spondylitis, an arthritis that primarily affects the spine.
The biopharmaceutical unit of Samsung reported that Brenzys had similar efficacy and safety to the original medicine in a phase 3 clinical trial carried out in 10 countries with 596 patients with rheumatoid arthritis.
By Hwang You-mee (glamazon@heraldcorp.com)
![[Herald Interview] Mistakes turn into blessings in street performance, director says](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/28/20240428050150_0.jpg&u=)
